Zealand Pharma A/S
OTC:ZLDPF

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
OTC:ZLDPF
Watchlist
Price: 100.51 USD 0.71% Market Closed
Market Cap: 7.1B USD
Have any thoughts about
Zealand Pharma A/S?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-33.7
Current
-15.9
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-33.7
=
Enterprise Value
36.4B DKK
/
EBITDA
-1.1B DKK
All Countries
Close
Market Cap EV/EBITDA
DK
Zealand Pharma A/S
OTC:ZLDPF
44.5B USD -33.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 567.6
US
Abbvie Inc
NYSE:ABBV
310.3B USD 15.2
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 21
US
Epizyme Inc
F:EPE
94.1B EUR -514.6
AU
CSL Ltd
ASX:CSL
133.7B AUD 19.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 15.1
US
Seagen Inc
F:SGT
39.3B EUR -58.8
NL
argenx SE
XBRU:ARGX
36.2B EUR -110
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
OTC:ZLDPF
Average EV/EBITDA: 16.2
Negative Multiple: -33.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 567.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.6
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-48.1
2-Years Forward
EV/EBITDA
83.1
3-Years Forward
EV/EBITDA
121.4

See Also

Discover More